Cutaneous adverse drug reactions are among the most common adverse drug reactions. Thise reactions to drugs can comprise a broad spectrum of clinical and histopathological features, with an important capacity to mimic numerous dermatological diseases, making the diagnose very difficult. We present the case of a patient, under immunomodulating treatment (TNFalpha antagonist and leflunomide), with a muco-cutaneous lichen planus-like eruption.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Oral lichen planus-like lesions in skin of color: a review.
Int J Dermatol
November 2024
Department of Pathology, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
Article Synopsis
- Lichenoid lesions in dermatology are characterized by a violaceous color due to basal cell damage and inflammation beneath the epithelium.
- These lesions are primarily associated with lichen planus but can appear in various other disorders, which complicates diagnosis.
- Accurate diagnosis is crucial for treatment, and dermatologists use clinical features, patient history, and additional tests like histopathology to differentiate these conditions from mimickers.
Case report: Lichenoid eruption under immunotherapy with MK-4830 and pembrolizumab in a breast cancer patient.
Front Pharmacol
August 2024
Department of Dermatology, Venereology and Allergology, Faculty of Medicine, Medical University of Gdansk, Gdansk, Poland.
Background: Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment, yet they can induce immune-related adverse events (irAEs), including cutaneous toxicities such as lichenoid eruptions. Pembrolizumab, a PD-1 inhibitor, is known for its association with lichen-planus-like reactions, while the side effect profile of combining immunotherapy with MK-4830, a novel fully human IgG4 monoclonal antibody that targets ILT-4, remains limited.
Case Report: We present a case of a 47-year-old female with metastatic breast cancer who developed a grade 2 Common Terminology Criteria for Adverse Events (CTCAE) lichenoid reaction after 9 months of MK-4830 and pembrolizumab use.
Generalized Lichen Planus-Like Eruption Related to Anti-Tubercular Drugs.
Indian J Dermatol
January 2023
Department of Dermatology, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, China E-mail:
Cutaneous manifestations associated with immune checkpoint inhibitors.
Front Immunol
March 2023
Department of Environmental Immuno-Dermatology, Yokohama City University School of Medicine, Yokohama, Japan.
Immune checkpoint inhibitors (ICIs) are monoclonal antibodies that block key mediators of tumor-mediated immune evasion. The frequency of its use has increased rapidly and has extended to numerous cancers. ICIs target immune checkpoint molecules, such as programmed cell death protein 1 (PD-1), PD ligand 1 (PD-L1), and T cell activation, including cytotoxic T-lymphocyte-associated protein-4 (CTLA-4).
View Article and Find Full Text PDFPRAME immunohistochemistry can distinguish melanocytic pseudonests of lichenoid reactions from melanoma in situ.
J Cutan Pathol
May 2023
Department of Dermatology, Yale University School of Medicine, New Haven, Connecticut, USA.
Article Synopsis
- Scientists are trying to tell the difference between two skin issues: one that looks like a harmless grouping of cells and another that is a type of skin cancer called melanoma.
- They did a study using a special test called PRAME to help identify these differences in skin samples.
- The results showed that PRAME can be a helpful tool, as it correctly identified the differences between the two conditions most of the time.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!